Immune checkpoint inhibitors are associated with durable and well-tolerated responses in metastatic urothelial carcinoma. Predicting which patients respond to therapy has been challenging; however, progress has been made using programmed cell death 1 ligand 1 as a biomarker and a second generation of biomarkers, which are being assessed.
This is a preview of subscription content, log in via an institution to check access.
References
Sternberg, C. N. et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J. Clin. Oncol. 19, 2638–2646 (2001).
Powles, T. et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515, 558–562 (2014).
Balar, A. V. et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 389, 67–76 (2017).
Powles, T. et al. Immune checkpoint inhibition in metastatic urothelial cancer. Eur. Urol. 72, 477–481 (2017).
Bellmunt, J. et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N. Engl. J. Med. 376, 1015–1026 (2017).
Powles, T. et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 391, 748–757 (2018).
Mariathasan, S. et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544–548 (2018).
Rosen, D. B. et al. Quantitative measurement of alterations in DNA damage repair (DDR) pathways using single cell network profiling (SCNP). J. Transl Med. 12, 184 (2014).
Robertson, A. G. et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 171, 540–556 (2017).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
T.P. has received research funding and honoraria from Merck Pfizer, AstraZenca, Bristol-Myers Squibb, Roche, Novartis, and GlaxoSmithKline. L.M. declares no competing interests.
Rights and permissions
About this article
Cite this article
Powles, T., Morrison, L. Biomarker challenges for immune checkpoint inhibitors in urothelial carcinoma. Nat Rev Urol 15, 585–587 (2018). https://doi.org/10.1038/s41585-018-0056-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41585-018-0056-3
- Springer Nature Limited
This article is cited by
-
RNA N6-methyladenosine modifications in urological cancers: from mechanism to application
Nature Reviews Urology (2024)
-
Tumor-associated neutrophils suppress CD8+ T cell immunity in urothelial bladder carcinoma through the COX-2/PGE2/IDO1 Axis
British Journal of Cancer (2024)
-
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Signal Transduction and Targeted Therapy (2022)
-
PD-L1 expression in bladder primary in situ urothelial carcinoma: evaluation in BCG-unresponsive patients and BCG responders
Virchows Archiv (2020)
-
Molecular and histopathology directed therapy for advanced bladder cancer
Nature Reviews Urology (2019)